Growth Research
CJC/Ipa BlendMod GRF 1-29 + IpamorelinModified GRF + Ipamorelin

CJC-1295 / Ipamorelin

(1 customer review)

$59.99

Growth Hormone Secretagogue Peptide

Out of stock

Description

MECHANISM OF ACTION
How CJC-1295 / Ipamorelin Works
Understanding the biological pathways and mechanisms
CJC
CJC-1295 (GHRH Pathway)
CJC-1295 is a 30-amino acid GHRH analog with Drug Affinity Complex (DAC) technology that extends half-life to 6-8 days. It stimulates pituitary GHRH receptors to amplify the natural GH pulse amplitude while maintaining pulsatile release patterns.
IPA
Ipamorelin (Ghrelin Pathway)
Ipamorelin is a selective growth hormone secretagogue that activates the ghrelin/GHS receptor (GHSR). Unlike other GHSs, Ipamorelin selectively stimulates GH release without significantly affecting cortisol, prolactin, or ACTH levels.
SYN
Dual-Pathway Synergy
Combining CJC-1295 (GHRH pathway) with Ipamorelin (Ghrelin pathway) creates synergistic GH stimulation. The two pathways converge on somatotroph cells from different receptor systems, amplifying GH release beyond what either compound achieves alone.
KEY DISCOVERY
The Gold Standard GH Combination
CJC-1295/Ipamorelin is the most widely studied growth hormone secretagogue combination in peptide research. By targeting both the GHRH and Ghrelin receptor pathways simultaneously, this blend produces robust, physiological GH elevation with a favorable selectivity profile.
CLINICAL DATA
What Research Has Shown
Published findings from peer-reviewed studies on CJC-1295 / Ipamorelin
2x
Dual GH Pathways
6-8d
CJC-1295 Half-Life
99%+
Purity Each
GH Stimulation96%
IGF-1 Elevation93%
Selectivity (low cortisol)91%
Pulsatile Pattern Maintenance89%
CJC-1295 30-amino acid GHRH analog
Ipamorelin 5-amino acid GHS peptide
CJC-1295 Half-Life 6-8 days (with DAC)
Ipamorelin Selectivity GH-specific (minimal cortisol/prolactin)
Combined Mechanism GHRH + Ghrelin receptor synergy
GH Release Pattern Amplified pulsatile release
SAFETY DATA
Safety Profile from Research
Reported adverse effects and safety considerations for CJC-1295 / Ipamorelin
<8%
Injection Site Reaction
<5%
Headache
<4%
Flushing / Warmth
<3%
Water Retention
GH-Related Effects
Sustained GH elevation may cause water retention, joint stiffness, and carpal tunnel-like symptoms. These effects are typically dose-dependent and resolve with dose adjustment.
IGF-1 Monitoring
The combination produces significant IGF-1 elevation. Regular monitoring is recommended in research protocols, particularly with extended use or in combination with other GH-stimulating compounds.
Both CJC-1295 and Ipamorelin have demonstrated favorable safety profiles individually. Ipamorelin is particularly noted for its selectivity — stimulating GH without significantly affecting cortisol, prolactin, or ACTH levels.
COMPOUND PROFILE
Compound Information
What is CJC-1295 / Ipamorelin?
This blend combines CJC-1295, a 30-amino acid GHRH analog with DAC (Drug Affinity Complex) technology for extended half-life, with Ipamorelin, a 5-amino acid selective growth hormone secretagogue. CJC-1295 amplifies GH pulse amplitude through the GHRH pathway while Ipamorelin increases GH pulse frequency through the ghrelin receptor — creating synergistic GH stimulation.
CJC-1295 Structure 30 amino acids + DAC
Ipamorelin Structure 5 amino acids (pentapeptide)
CJC-1295 Half-Life 6-8 days
Ipamorelin Half-Life ~2 hours
Combined Mechanism GHRH + GHSR synergy
Formulation Lyophilized Powder
Purity 99%+ (each component)
Storage & Stability
Store lyophilized blend at -20°C. After reconstitution with bacteriostatic water, store at 2-8°C and use within 30 days. The CJC-1295 component provides extended activity while Ipamorelin provides acute GH pulses.
CURRENT STATUS
Where It Stands
CJC-1295/Ipamorelin is the most commonly studied GH secretagogue combination in peptide research. The dual-pathway approach (GHRH + Ghrelin) produces more robust GH responses than either compound alone, while Ipamorelin’s selectivity minimizes unwanted hormonal effects. Neither component is FDA-approved for therapeutic use.
COMMON QUESTIONS
Frequently Asked Questions
Common questions about CJC-1295 / Ipamorelin in research
Why combine CJC-1295 with Ipamorelin?
CJC-1295 and Ipamorelin work through different GH-releasing pathways (GHRH and Ghrelin receptors respectively). Combining them creates synergistic GH stimulation — amplifying both the amplitude and frequency of GH pulses beyond what either achieves alone.
What makes Ipamorelin selective?
Unlike other GH secretagogues (GHRP-6, GHRP-2), Ipamorelin selectively stimulates GH without significantly raising cortisol, prolactin, or ACTH. This selectivity reduces side effects associated with other GHS compounds.
What is the DAC in CJC-1295?
DAC (Drug Affinity Complex) is a chemical modification that allows CJC-1295 to bind to albumin in the bloodstream, extending its half-life from minutes to 6-8 days. This provides sustained GHRH receptor stimulation.
How does this differ from direct GH injection?
This combination stimulates the pituitary to produce endogenous GH in natural pulsatile patterns, unlike direct GH injection which provides a constant exogenous supply and suppresses natural production.
Is this combination FDA-approved?
No. Neither CJC-1295 nor Ipamorelin is FDA-approved. This product is sold for research purposes only and is not intended for human consumption or therapeutic use.
PUBLISHED RESEARCH
Sources & References
Peer-reviewed publications referenced in this overview
Journal of Clinical Endocrinology & Metabolism
CJC-1295: A Long-Acting GHRH Analog
Teichman et al., 2006 — Pharmacokinetic characterization
European Journal of Endocrinology
Ipamorelin: A Selective Growth Hormone Secretagogue
Raun et al., 1998 — Selectivity profile study
Growth Hormone & IGF Research
Synergistic GH Release from Combined GHRH and GHS Administration
Bowers et al., 2004 — Combination synergy study
Hormone Research
Growth Hormone Secretagogues: History, Mechanism, and Clinical Development
Smith, 2005 — Comprehensive GHS review
Important Research Notice
This product is sold strictly for research, educational, and scientific purposes only. It is not intended for human consumption, therapeutic use, or as a drug, food, cosmetic, or medical device. Not approved by the FDA for any clinical or diagnostic use. All research must comply with applicable local, state, and federal regulations. Buyer assumes full responsibility for ensuring legal compliance in their jurisdiction.

Additional information

Weight .15 lbs
Dosage

10MG

1 review for CJC-1295 / Ipamorelin

  1. Verified Researcher's avatar

    Verified Researcher

    Excellent purity and fast shipping. CJC-1295/Ipamorelin exceeded my research expectations.

Add a review

Your email address will not be published. Required fields are marked *